Table 5.
Chou-Talalay statistics on the mean IC50 values between cytochalasin B, 21, 22-dihydrocytochalasin B, doxorubicin, and paclitaxel against SKOV3 and SKVLB1 human ovarian carcinoma
| Cell line | Cytochalasin (μM) | Clinically approved agent (μM) | DRI Cyta | DRI CAAb | CI |
|---|---|---|---|---|---|
| SKOV3 | 0.6 CB | 0.0067 ADR | 3.46 | 8.20 | 0.41 |
| 0.6 CB | 0.0023 Tax | 3.46 | 6.99 | 0.43 | |
| 0.76 DiHCB | 0.0065 ADR | 5.23 | 10.9 | 0.28 | |
| 0.76 DiHCB | 0.0030 Tax | 5.23 | 12.5 | 0.27 | |
| SKVLB1 | 0.6 CB | 0.30 ADR | 4.07 | 15.7 | 0.30 |
| 0.6 CB | 0.40 Tax | 4.07 | 19.7 | 0.29 | |
| 1.12 DiHCB | 0.29 ADR | 5.27 | 17.5 | 0.25 | |
| 1.12 DiHCB | 0.30 Tax | 5.27 | 22.7 | 0.23 |
Mean values for drug concentrations, dose reduction indices, and combination indices were derived from the points used in the IC50 isobolograms, excluding single agent administrations
CI combination index
aDose reduction index for the indicated cytochalasin
bDose reduction index for the indicated currently approved agent